



European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

Document Date: London, 12 November 2009
Doc.Ref.: EMEA/COMP/152652/2004 Rev.1

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in March 2009 on request of the Sponsor.

Committee for Orphan Medicinal Products

Public summary of positive opinion for orphan designation of Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3) for the treatment of chronic myeloid leukaemia

On 21 December 2004, orphan designation (EU/3/04/252) was granted by the European Commission to Accelsiors CRO & Consultancy Services GmbH, Germany, for Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3) for the treatment of chronic myeloid leukaemia.

What is chronic myeloid leukaemia?

Chronic myeloid leukaemia is a disease in which cancer cells are found in the blood and in the bone marrow. The bone marrow is the spongy tissue inside the large bones in the body. Normally, the bone marrow makes cells called “blasts” that mature into several different types of blood cells that have specific functions in the body. These include red cells, white cells and platelets. Red blood cells carry oxygen and other materials to all tissues of the body. White blood cells fight infection. Platelets make the blood clot. When leukaemia develops, the bone marrow produces large numbers of abnormal blood cells. There are several types of leukaemias. In myeloid leukaemia blasts that are developing into white blood cells called granulocytes, are affected. The blasts do not mature and become too many. These blast cells are then found in the blood and also accumulate in the bone marrow. The disease can develop very slowly, which is why it is called “chronic” myeloid leukaemia. Chronic myeloid leukaemia is life-threatening.

What is the estimated number of patients affected by the condition?

At the time of designation, chronic myeloid leukaemia affected approximately 0.4 in 10,000 people in the European Union (EU)*. This is equivalent to a total of around 18,000 people, and is below the threshold for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and knowledge of the Committee for Orphan Medicinal Products (COMP).

What treatments are available?

Treatment for leukaemia is complex and depends on a number of factors including the type of leukaemia, the extent of the disease and whether the leukaemia has been treated before. It also depends on the age, the symptoms, and the general health of the patient. At the time of submission of the application for orphan drug designation authorised treatments of chronic myeloid leukaemia included chemotherapy agents (using drugs to kill cancer cells) and immunotherapy agents (using drugs that

*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 25), Norway, Iceland and Liechtenstein. This represents a population of 459,700,000 (Eurostat 2004).

stimulate the body's own immune system to kill cancer cells). Sometimes a combination of immunotherapy and chemotherapies may be used. Another product is also used which blocks (inhibits) growth signals within cancer cells and prevents a series of chemical reactions that cause the cell to grow and divide thus stopping cancer cells growth. Bone marrow transplantation is also used. Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3) could be of potential significant benefit for the treatment of chronic myeloid leukaemia because it may act in a different way and it might improve the long-term outcome of patients. This assumption will have to be confirmed at the time of marketing authorisation. This will be necessary to maintain the orphan status.

How is this medicine expected to work?

Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3) is a peptide, which is a part of a protein. It is similar to a part of a protein, present on the surface of certain cells, such as cancer cells. It is expected to work as a vaccine, thus upon administration of this peptide, the body's defense system (immune system) will recognize this peptide as a foreign body and react against this peptide. Since part of this foreign body is similar to parts of the protein on the cancer cells, it is expected that the immune system will not only recognize the vaccine as foreign, but also the cancer cells. The body's immune system could then kill these cancer cells.

What is the stage of development of this medicine?

The effects of Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3) were evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials in patients with chronic myeloid leukaemia were ongoing.

Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3) was not marketed anywhere worldwide for the treatment of chronic myeloid leukaemia or designated as orphan medicinal product elsewhere for this condition, at the time of submission.

According to Regulation (EC) No 141/2000 of 16 December 1999, the Committee for Orphan Medicinal Products (COMP) adopted on 11 November 2004 a positive opinion recommending the grant of the above-mentioned designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the Community) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

For more information:

Sponsor's contact details:

Accelsiors CRO & Consultancy Services GmbH

Hammersbacher Fussweg 24

82467 Garmisch-Partenkirchen

Germany

Telephone: +49 88 21 94 30 271

Telefax: +49 88 21 94 30 272

E-mail: accelsiors@t-online.de

Patients' associations contact points:

Leukaemia Care

2 Shrubbery Avenue

Worcester

WR1 1QH

United Kingdom

0800 169 6680 (freephone for UK residents)

Telephone: +44 19 05 33 00 03 / +44 84 57 67 32 03

Telefax: +44 19 05 33 00 90

E-mail: enquiries@leukaemiaCARE.org.uk

DLH : Deutsche Leukämie- und Lymphom-Hilfe e.V.

Thomas-Mann-Straße 40

53111 Bonn

Germany

Telephone: +49 22 83 90 440

Telefax: +49 22 83 90 44 22

E-mail: info@leukaemie-hilfe.de

Associazione Italiana contro le Leucemie-linfomi e mieloma ONLUS

Via Ravenna 34

00161 Roma

Italy

Telephone: +39 06 44 03 763

Telefax: +39 06 44 04 226

E-mail: ail@ail.it

**Translations of the active ingredient and indication in all EU languages
and Norwegian and Icelandic**

Language	Active Ingredient	Indication
English	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3)	Treatment of chronic myeloid leukemia
Czech	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptid, sekvence 169-177, proteinázy 3)	Léčba chronické myeloidní leukémie
Danish	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptid, sekvens 169-177, af proteinase 3) eukæmiassocieret PR1-antigen	Behandling af kronisk myeloid leukæmi
Dutch	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequentie 169-177, van proteinase 3)	Behandeling van chronische myeloïde leukemie
Estonian	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Proteinaas 3 PR1 nanopeptiid, järjestusega 169-177)	Kroonilise müeloidse leukeemia ravi
Finnish	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (proteinaasi 3 Pr1 nanopeptidi, 169-177 sekvenssi)	Kroonisen myelooisen leukemian hoito
French	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (nanopeptide Pr1, séquence 169-177 de la protéinase 3)	Traitement de la leucémie myéloïde chronique
German	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 Nanopeptid, Sequenz 169-177, der Proteinase 3)	Behandlung der chronischen myeloischen Leukämie
Greek	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 νοναπεπτίδιο, αλληλουχίας 169-177 της πρωτεΐνάσης 3)	Θεραπεία της χρόνιας μυελοειδούς λευχαιμίας
Hungarian	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptid, proteináz3 169-177 szekvenciája)	Krónikus myeloid leukémia kezelése
Italian	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequenza 169-177, di proteinasi 3)	Trattamento della leucemia mieloide cronica
Latvian	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (proteināzes 3 Pr1 nanopeptīds, virkne 169-177)	Hroniskas mieloleikozes ārstēšana
Lithuanian	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptidas, proteinazės 3 seka 169-177)	Lėtinės mielocitinės leukemijos gydymas
Polish	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (nanopeptyd w sekwencji 169-177 proteinazy 3)	Leczenie przewlekłej białaczki szpikowej
Portuguese	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptido, sequência 169-177, da proteinase 3)	Tratamento da leucemia mielóide crónica

Slovak	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptid, sekvencia 169-177, proteinázy 3)	Liečba chronickej myeloidnej leukémie
Slovenian	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptid, sekvenca 169-177 proteinaze 3)	Zdravljenje kronične mieloične levkemije
Spanish	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (nanopéptido Pr1, secuencia 169-177, de la proteinasa 3)	Tratamiento de la leucemia mieloide crónica
Swedish	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptid, sekvens 169-177, av proteinasa 3)	Behandling av kronisk myeloid leukemi
Norwegian	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptid, sekvens 169-177 av proteinase 3)	Behandling av kronisk myelogen leukemi
Icelandic	Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptíð, röð 169-177, af próteinasa 3)	Meðferð við langvinnu hvítblæði í beinmerg